Semaglutide—the active compound in many GLP-1 drugs—may reduce strength even when muscle size stays the same. The findings emphasize the need for human studies that measure muscle function, not just mass.
The post GLP-1 Drug Semaglutide Linked to Reduced Muscle Strength in Mice appeared first on GEN -…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
This week on STAT’s podcast The Readout LOUD, hear about Biomarin’s new chief business officer, Recursion’s AI bona fides, and new findings on a GLP-1 and diabetes risk. Click here to view original post Click […]
Celebrating the bold leaders shaping the future through the world’s most ground-breaking companies WEST VALLEY, Utah, July 9, 2025 /PRNewswire/ — Ernst & Young LLP (EY US) today announced that John Lippert, Chief Technical Officer […]
ST. GEORGE, Utah, Feb. 15, 2024 /PRNewswire/ — Southwest Behavioral Health Center (“SBHC”) is a public provider of comprehensive, integrated mental health and addiction services, offering outpatient, residential, and community-based programs and services to low-income […]
Copyright © 2026 Biotech Networks
